Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.50 |
| ▸ | OGT | O15294 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4233827 | 0.94 | ALDH1A1 (0.50) | CYP1A2CYP2D6CYP2C19PLAAT3PLAAT5 | |
| Fumaric Acid SCHEMBL4233829 | 0.94 | ALDH1A1 (0.50) | CYP1A2CYP2D6CYP2C19PLAAT3PLAAT5 | |
| SCHEMBL4225488 | 0.89 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C19ALDH1A1LMNA | |
| SCHEMBL4227398 | 0.88 | L3MBTL1 (0.49) | CYP1A2CYP2C19ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11350168 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2D6CYP2C19PLAAT3PLAAT5 | |
| Fumaric Acid SCHEMBL4231652 | 0.84 | ALDH1A1 (0.58) | CYP2D6CYP2C19ALDH1A1LMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL4231644 | 0.84 | ALDH1A1 (0.58) | CYP2D6CYP2C19ALDH1A1LMNASMN1; SMN2 | |
| Fumaric Acid SCHEMBL4226828 | 0.84 | TDP1 (0.58) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| Fumaric Acid SCHEMBL4232774 | 0.84 | SMN1; SMN2 (0.56) | GABRB1GABRB2SMN1; SMN2 | |
| Fumaric Acid SCHEMBL4232765 | 0.84 | SMN1; SMN2 (0.56) | GABRB1GABRB2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| CN-101253147-A | Organic compounds | NOVARTIS PHARMA AG (CH) | 2008-08-27 | — | — | CN | disclosed |
| EP-1924551-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025709-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | CYP1A2 604/4885CYP2D6 111/4885CYP2C19 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.